Targeting fibroblast growth factor pathways in endometrial cancer

Curr Probl Cancer. Jan-Feb 2017;41(1):37-47. doi: 10.1016/j.currproblcancer.2016.11.002. Epub 2016 Nov 11.

Abstract

Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC.

Keywords: Angiogenesis; Endometrial cancer; Fibroblast growth factor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Endometrial Neoplasms / drug therapy*
  • Endometrial Neoplasms / genetics
  • Endometrial Neoplasms / metabolism
  • Endometrial Neoplasms / pathology
  • Female
  • Fibroblast Growth Factors / antagonists & inhibitors*
  • Fibroblast Growth Factors / genetics
  • Fibroblast Growth Factors / metabolism
  • Humans
  • Molecular Targeted Therapy / methods*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / genetics
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Fibroblast Growth Factors